Intercept Pharmaceuticals Inc (NASDAQ:ICPT) – Research analysts at Cantor Fitzgerald raised their FY2018 EPS estimates for shares of Intercept Pharmaceuticals in a research report issued on Thursday. Cantor Fitzgerald analyst E. Piros now expects that the biopharmaceutical company will post earnings per share of ($12.61) for the year, up from their prior forecast of ($13.50). Cantor Fitzgerald has a “Hold” rating and a $58.00 price target on the stock.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.04). Intercept Pharmaceuticals had a negative return on equity of 207.27% and a negative net margin of 275.18%. The firm had revenue of $37.69 million during the quarter, compared to analysts’ expectations of $39.01 million. During the same period in the previous year, the firm earned ($4.84) EPS. The firm’s quarterly revenue was up 173.1% on a year-over-year basis.
Other research analysts also recently issued research reports about the stock. Deutsche Bank initiated coverage on shares of Intercept Pharmaceuticals in a research report on Tuesday, December 12th. They issued a “buy” rating and a $106.00 price objective on the stock. Wedbush reaffirmed a “buy” rating and issued a $253.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, December 22nd. Cowen reaffirmed a “buy” rating and issued a $112.00 price objective on shares of Intercept Pharmaceuticals in a research report on Wednesday, November 1st. Laidlaw raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $90.00 price objective on the stock in a research report on Wednesday, November 1st. Finally, Credit Suisse Group set a $167.00 target price on shares of Intercept Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, January 22nd. Four equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $128.75.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up $0.52 during trading on Monday, hitting $61.16. 714,800 shares of the stock were exchanged, compared to its average volume of 1,075,321. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95. Intercept Pharmaceuticals has a 52-week low of $51.05 and a 52-week high of $135.59. The stock has a market cap of $1,560.00, a P/E ratio of -4.25 and a beta of -2.13.
Several hedge funds have recently added to or reduced their stakes in ICPT. Senvest Management LLC purchased a new stake in shares of Intercept Pharmaceuticals in the 3rd quarter valued at $33,883,000. First Trust Advisors LP boosted its holdings in shares of Intercept Pharmaceuticals by 101.5% in the 4th quarter. First Trust Advisors LP now owns 605,454 shares of the biopharmaceutical company’s stock valued at $35,371,000 after acquiring an additional 304,999 shares during the last quarter. Pinnacle Associates Ltd. purchased a new stake in shares of Intercept Pharmaceuticals in the 4th quarter valued at $12,577,000. Sarissa Capital Management LP purchased a new stake in shares of Intercept Pharmaceuticals in the 4th quarter valued at $10,649,000. Finally, Emerald Advisers Inc. PA purchased a new stake in shares of Intercept Pharmaceuticals in the 4th quarter valued at $9,497,000. 78.39% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/20/intercept-pharmaceuticals-inc-icpt-to-post-fy2018-earnings-of-12-61-per-share-cantor-fitzgerald-forecasts.html.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.